Why Novanta’s latest earnings moved the stock
Novanta (NOVT) caught investor attention after reporting quarterly revenue growth that topped analyst expectations, even as EBITDA guidance for the next quarter came in below consensus and management doubled down on acquisition and growth priorities.
See our latest analysis for Novanta.
The share price has gained 19.1% over the past month and 43.7% year to date, with the 1 year total shareholder return of 32.9% contrasting with a 3 year total shareholder return that is slightly negative. This suggests momentum has recently rebuilt after a softer multi year period.
If Novanta’s recent move has you thinking about where growth and automation could show up next, it may be worth scanning 35 robotics and automation stocks
With the stock up sharply this year, trading at $159.70 and only a small 7.4% gap to the average analyst price target of $171.50, the key question is whether there is still a buying opportunity here or if the market is already pricing in most of Novanta’s potential.
Most Popular Narrative: 2% Overvalued
The most followed narrative pegs Novanta’s fair value at $157, slightly below the last close at $159.70, which frames the current rally as already pricing in much of the expected earnings power.
Rapid adoption of robotics and automation in manufacturing and healthcare (including AI-enabled warehouse automation, surgical robotics, and future humanoid robotics) is accelerating demand for Novanta's advanced sensing and precision motion technologies. The company's design wins and multi-year contracts (e.g., $50M warehouse robotics deal, multiple new design wins in physical AI and robotics) position it to grow revenue at above-market rates through 2026 and beyond.
Curious what kind of revenue runway and margin shift would need to play out to back that fair value. The narrative leans on stronger profitability, faster earnings growth than the wider market, and a future earnings multiple that assumes investors stay comfortable paying up for this mix of robotics and medical exposure.
Result: Fair Value of $157 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on Novanta offsetting flat organic revenue trends while managing trade and tariff pressures that could affect margins and cash generation.
Find out about the key risks to this Novanta narrative.
Next Steps
Mixed views on risk and reward so far. If you want your own take before sentiment shifts again, review the upside and the concerns in the 1 key reward and 1 important warning sign.
Looking for more investment ideas?
If Novanta has sharpened your focus on quality, do not stop here. Your next idea might be sitting in plain sight on another watchlist.
- Hunt for potential bargains that pair quality with pricing that may still be attractive by scanning the 49 high quality undervalued stocks.
- Target steady income opportunities by reviewing the 10 dividend fortresses that could help support a portfolio focused on cash returns.
- Prioritise resilience by checking the 67 resilient stocks with low risk scores designed to surface companies with lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com